INM InMed: מקדם חוב לטווח ארוך להון

The development of biosynthesis-based dermatological agents remains in the R&D stage, which makes scaling costly in the absence of sales. The confirmed price history on this chart, where the indicator is 0.00, helps track this process. InMed Pharmaceuticals (INM) relies on the creation of pure cannabinoids for eye and skin therapy, possessing significant pricing power. Revenues are generated through the innovative production of rare components.

To build a resilient portfolio, I evaluate financial leverage through long-term debt load. This ratio compares liabilities with a maturity of over one year against the amount of equity. For InMed Pharmaceuticals (INM), such a structure is critical when financing the development of drugs for glaucoma and dermatological diseases. The trend of the long-term debt-to-equity ratio determines the extent of the biotech startup's dependence on borrowed financing.